Brought to you by 
Aeglea's Series B round brings in $44mm
29 Jun 2015
Executive Summary
Aeglea Biotherapeutics Inc. (developing drugs for inborn errors of metabolism (IEM) and therapies targeting tumor metabolism) raised $44mm through its Series B round. A total of 54 investors participated, including returning backers Lilly Ventures and Novartis Venture Fund (co-leads) and UT Horizon Fund, along with new buyers OrbiMed, Jennison Associates, Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group, and Cowen Investments.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aeglea's Series B round brings in $44mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice